<DOC>
	<DOCNO>NCT01995838</DOCNO>
	<brief_summary>This multicenter , multiple dose , randomize , double-blind , placebo-controlled , parallel-group , Bayesian adaptive , dose response study subject chronic insomnia . Subjects randomize 1 6 dos E2006 ( 1 mg , 2.5 mg , 5 mg , 10 mg , 15 mg , 25 mg ) placebo .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-blind , Placebo-controlled , Parallel-group , Bayesian Adaptive Randomization Design , Dose Response Study Efficacy E2006 Adults Elderly Subjects With Chronic Insomnia</brief_title>
	<detailed_description>The study 2 phase , Prerandomization Randomization . The Prerandomization Phase last 21 day consist Screening Period ( Days -21 -2 ) Baseline Period ( Day -1 ) . Following Baseline Period , eligible subject randomize , double-blind manner , receive E2006 placebo 15 night Treatment Period ( Days 1 15 ) , subject receive placebo , single-blind manner , 2 night ( Days 16 17 ) Rebound Insomnia Assessment Period ( Days 16 18 ) . Subjects receive treatment Follow-up Period ( Days 19 29 ) . All subject come clinic screening procedure . During Screening Period , subject complete Sleep Diary day . Polysomnographic sleep measure Screening Period 2 consecutive night Day -9 Day -3 . These 8-hour polysomnograms ( PSGs ) start median habitual bedtime calculate response Sleep Diary complete 7 day immediately prior first PSG night . Subjects may leave clinic screening/baseline PSG night .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Male female subject age 18 80 year time inform consent 2 . Meets 5th Edition Diagnostic Statistical Manual Mental Disorders ( DSM5 ) criteria Insomnia Disorder 3 . Subjective Sleep Onset Latency ( sSOL ) typically great equal 30 minute last 4 week and/or subjective WASO ( sWASO ) typically great equal 60 minute last 4 week 4 . Regular time bed 6.5 9.0 hour 5 . Regular bedtime 21:00 24:00 regular waketime 05:00 09:00 6 . Insomnia Severity Index ( ISI ) score great equal 15 Screening 7 . Confirmation current insomnia symptom determine response Sleep Diary complete 7 night prior first screening/baseline PSG 8 . Objective ( PSG ) evidence insomnia screening/baseline PSGs follow : 1 . LPS average great equal 30 minute 2 consecutive screening/baseline PSGs , neither night lesser 15 minute and/or 2 . WASO average great equal 30 minute 2 consecutive screening/baseline PSGs , neither night lesser 20 minute 3 . SE average less equal 85 % 2 consecutive screening/baseline PSGs , neither night great 87.5 % 9 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use two highly effective method contraception 10 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 11 . Provide write informed consent 12 . Willing stay bed least 8 hour night spend clinic 13 . Willing able comply aspect protocol Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Females pregnant ( positive betahuman chorionic gonadotropin [ BhCG ] test ) breastfeed 2 . Any lifetime diagnosis sleeprelated breathe disorder , periodic limb movement disorder , restless legs syndrome , nightmare disorder , sleep terror disorder , sleepwalk disorder , rapid eye movement ( REM ) behavior disorder , narcolepsy 3 . Aged 18 64 year : ApneaHypopnea Index great equal 10 , Periodic Limb Movements Arousal Index great equal 10 first ( diagnostic ) PSG night Screening . Aged 65 80 year : ApneaHypopnea Index great 15 , Periodic Limb Movements Arousal Index great 15 first ( diagnostic ) PSG night Screening 4 . Beck Depression Inventory ( BDI ) II score great 19 Screening 5 . Beck Anxiety Inventory ( BAI ) score great 15 Screening 6 . Used prescription modality treatment insomnia , include cognitive behavioral therapy , within 2 week prior screening/baseline PSG , Screening Baseline 7 . Used medication sleep aid know effect sleep , within 2 week prior screening/baseline PSG , Screening Baseline 8 . Used prohibited prescription overthecounter concomitant medication within week prior first screening/baseline PSG . 9 . Transmeridian travel across 3 time zone 2 week prior Screening , plan travel across 3 time zone study 10 . Unwilling limit caffeine consumption lesser equal 600 mg caffeine ( approximately four 6oz cup caffeinated coffee , three 12oz caffeinated soda , three 8oz caffeinated tea beverage ) , avoid caffeine 18:00 throughout study , avoid caffeine 13:00 PSG visit 11 . Unwilling limit alcohol intake two few drink per day throughout study , refrain alcohol 3 hour prior bedtime home throughout study , alcohol day night spend clinic . A drink define approximately 12 oz ( 360 mL ) beer , 4 oz ( 120 mL ) wine , 1 oz ( 30 mL ) liquor . 12 . Any subject know history malaria travel country know malarial risk ( i.e. , designate 'high ' 'moderate ' risk country accord list available http : //www.cdc.gov/malaria ) within last year . 13 . A prolonged QT/QT interval correct heart rate ( QTc ) interval ( QTc great 450 m ) demonstrate repeat electrocardiogram ( ECG ) Screening ( repeat initial ECG indicate QTc interval great 450 m ) . A history risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history long QT Syndrome ) use concomitant medication prolong QT/QTc interval . 14 . Any suicidal ideation intent without plan Screening , Baseline , within 6 month Screening ( i.e. , answer `` Yes '' question 4 5 Suicidal Ideation section ColumbiaSuicide Severity Rating Scale [ CSSRS ] ) 15 . Any lifetime suicidal behavior ( per Suicidal Behavior Section CSSRS ) 16 . Evidence clinically significant disease ( e.g. , cardiac , respiratory , gastrointestinal , renal disease ) opinion investigator ( ) could affect subject 's safety interfere study assessment 17 . Hypersensitivity study drug excipients 18 . Any history medical condition concomitant medical condition opinion investigator ( ) would compromise subject 's ability safely complete study 19 . Scheduled surgery study 20 . Known human immunodeficiency virus ( HIV ) positive 21 . Active viral hepatitis ( B C ) demonstrate positive serology 22 . Psychotic disorder ( ) unstable recurrent affective disorder ( ) evident use antipsychotic prior suicide attempt ( ) within approximately last 2 year 23 . History drug alcohol dependency abuse within approximately last 2 year 24 . Unwilling refrain use illegal ( legalize ) recreational drug study test positive illegal ( legalize ) drug Screening , Baseline , Day 14 25 . Currently enrol another clinical trial use investigational drug device within 30 day 5x halflife , whichever longer precede informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>Adults</keyword>
	<keyword>Elderly</keyword>
</DOC>